Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against atopic dermatitis (AD). The company has secured a No Objection Letter from Health Canada, authorizing its Clinical Trial Application for ABCL575, a next-generation monoclonal antibody designed for moderate-to-severe AD and potentially other autoimmune and inflammatory diseases.
A research scientist examining a biological sample to develop a new drug candidate.
ABCL575 stands out as an Fc-silenced, half-life extended antibody that targets the OX40 ligand, a key player in the inflammatory pathways that drive AD. By disrupting the OX40/OX40L interaction, ABCL575 aims to suppress T cell-mediated inflammation, a hallmark of the disease. Preclinical studies have demonstrated the antibody’s potent anti-inflammatory effects, strong safety profile, and an extended half-life, which could allow for less frequent dosing compared to existing therapies.
The upcoming Phase 1 trial, set to launch in the third quarter of 2025, will assess the safety and pharmacokinetics of ABCL575 in healthy volunteers via subcutaneous administration. AbCellera Biologics Inc.’s innovative approach could mark a significant advancement in the treatment landscape for atopic dermatitis and related immune disorders.
READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.
